EYSINS, Switzerland, April 3, 2025 /PRNewswire/ -- Today, AliveDx announces it has submitted 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the MosaiQ AiPlex ® ...

EYSINS, Switzerland, April 3, 2025 /PRNewswire/ --Today, AliveDx announces it has submitted 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the MosaiQ AiPlex ® ...

Detection of somatic low abundance mutations in early cancer development requires a discriminatory, specific, and high-throughput methodology. In this study we report specific, discriminatory ...

As sequencing projects of microbial organisms are being completed, a large number of genes of potential biological and medical relevance are classified as 'unknown' because their unique sequence and ...

EYSINS, Switzerland, Feb. 10, 2025 /PRNewswire/ -- AliveDx announces it has submitted 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the MosaiQ AiPlex ® Celiac ...

PathogenDx's breakthrough technology shifts the pathogen detection paradigm from microbial to molecular testing through its microarray assays, namely DetectX, EnviroX, and QuantX SANTA CLARA, ...

AliveDx, an established commercial-stage in-vitro diagnostics company, announces it has submitted 510(k) premarket notification to the US Food and Drug Administration (FDA) for the MosaiQ AiPlex ...

All reagents and multiplex microarray magazines are equipped with RFID tags to save time while avoiding manual errors. Unique combination of tests The MosaiQ AiPlex CTDplus assay enables a syndromic ...

The MosaiQ AiPlex CD is designed to improve the accuracy and speed of celiac disease diagnosis while simplifying laboratory workflows EYSINS, Switzerland, Feb. 10, 2025 /PRNewswire/ -- AliveDx ...